Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjectsPOSVAR, E. L; RADULOVIC, L. L; CILLA, D. D et al.Journal of clinical pharmacology. 1996, Vol 36, Num 8, pp 728-731, issn 0091-2700Article

Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemiaWANG, T; NAKAJIMA, K; LEARY, E. T et al.Clinical chemistry (Baltimore, Md.). 1999, Vol 45, Num 11, pp 1981-1987, issn 0009-9147Conference Paper

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and eveningCILLA, D. D; GIBSON, D. M; WHITFIELD, L. R et al.Journal of clinical pharmacology. 1996, Vol 36, Num 7, pp 604-609, issn 0091-2700Article

Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasmaLEARY, E. T; TAO WANG; BAKER, D. J et al.Clinical chemistry (Baltimore, Md.). 1998, Vol 44, Num 12, pp 2490-2498, issn 0009-9147Article

Effect of food on the bioavailability of atorvastatin, and HMG-CoA reductase inhibitorRADULOVIC, L. L; CILLA, D. D; POSVAR, E. L et al.Journal of clinical pharmacology. 1995, Vol 35, Num 10, pp 990-994, issn 0091-2700Article

Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproterolemic patients with decreased HDL cholesterol levelsSCHAEFER, E. J; LAMON-FAVA, S; COLE, T et al.Atherosclerosis. 1996, Vol 127, Num 1, pp 113-122, issn 0021-9150Article

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjectsCILLA, D. D; WHITFIELD, L. R; GIBSON, D. M et al.Clinical pharmacology and therapeutics. 1996, Vol 60, Num 6, pp 687-695, issn 0009-9236Article